Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically confirmed MAIPC~* Documented progressive disease in bone, soft tissue or PSA despite castrate levels of testosterone~* If LHRH agonist were used previously it must be kept~* Previous anti-androgen should be held at least 4 weeks for flutamida or cyproterone and 6 weeks for bycalumida~* Previous DES should be held for at least 4 weeks before partcipating in the trial~* Chemotherapy naive patients~* No prior radioisotope~* Less than 25% of bone marrow should be irradiated for prior palliative radiotherapy~* KPS\> 70%~* Adequate hematologic, hepatic and renal function~Exclusion Criteria:~* Patients with serious medical illness~* History of significant active cardiac disease~* History of gastrointestinal ulceration, bleeding or perforation~* History of myocardial infarctin within past 12 months~* Allergy to sulfonamides or to celecoxib or history of urticaria to any NSAID~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).